Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
2.005
+0.020 (1.01%)
Oct 19, 2026, 11:08 AM EDT - Market open
Larimar Therapeutics Employees
Larimar Therapeutics had 71 employees as of December 31, 2025. The number of employees increased by 6 or 9.23% compared to the previous year. That makes Larimar Therapeutics the 33,343rd largest employer in the world and 4,371st in the United States.
Employees
71
Change (1Y)
6
Growth (1Y)
9.23%
Revenue / Employee
n/a
Profits / Employee
-$2,431,056
Market Cap
209.29M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 71 | 6 | 9.23% |
| Dec 31, 2024 | 65 | 23 | 54.76% |
| Dec 31, 2023 | 42 | 16 | 61.54% |
| Dec 31, 2022 | 26 | -5 | -16.13% |
| Dec 31, 2021 | 31 | 3 | 10.71% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Protalix BioTherapeutics | 226 |
| Fate Therapeutics | 161 |
| Lyell Immunopharma | 161 |
| Zentalis Pharmaceuticals | 106 |
| Alector | 103 |
| Keros Therapeutics | 92 |
| Pyxis Oncology | 56 |
LRMR News
- 19 days ago - Larimar Therapeutics appoints John Harlow as COO - TheFly
- 19 days ago - Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer - GlobeNewsWire
- 4 weeks ago - Larimar Therapeutics assumed with an Outperform at Leerink - TheFly
- 2 months ago - Larimar Therapeutics price target lowered to $11 from $12 at Wedbush - TheFly
- 2 months ago - Larimar Therapeutics reports Q2 EPS (30c), consensus (38c) - TheFly
- 2 months ago - Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update - GlobeNewsWire
- 2 months ago - Larimar Therapeutics Earnings release: Q2 2026 - Filings
- 2 months ago - Larimar Therapeutics Quarterly report: Q2 2026 - Filings